Noxopharm Ltd (NOX)

Sydney
0.350
-0.020(-5.41%)
  • Volume:
    348,580
  • Bid/Ask:
    0.350/0.400
  • Day's Range:
    0.350 - 0.365

NOX Overview

Prev. Close
0.37
Day's Range
0.35-0.365
Revenue
5.75M
Open
0.36
52 wk Range
0.305-0.99
EPS
-0.04
Volume
348,580
Market Cap
102.28M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
345,131
P/E Ratio
-
Beta
2.03
1-Year Change
-38.46%
Shares Outstanding
292,237,950
Next Earnings Date
-
What is your sentiment on Noxopharm Ltd?
or
Market is currently closed. Voting is open during market hours.

Noxopharm Ltd Company Profile

Employees
0
Market
Australia

Noxopharm Limited is an Australia-based clinical-stage drug development company. The Company is focused on the treatment of cancer and cytokine release syndrome or septic shock. The Company is engaged in the drug development program, which focuses on the treatment of pancreatic cancer and glioblastoma. The Company's lead drug candidate is called Veyonda (NOX66), which is a therapy developed for chemotherapy and radiotherapy in the treatment of late-stage cancers. Its drug candidate is in Phase II clinical trials. The Company's four pillar oncology program include externally delivered radiation (DARRT) Internally delivered radiation (LuPIN), Checkpoint inhibitors (IONIC) and Chemotherapy (CEP).

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.